Mustang Bio MBIO
NASDAQ MBIO
$0.44 -0.01 (-2.24%)
As of: Nov 11, 2026 · 2:59 PM EST

Mustang Bio (MBIO) Restructuring Costs (2024)

Updated

Analysis

Mustang Bio (MBIO) Restructuring Costs (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Mustang Bio 3.03 Mn -60.03 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 1.04 Mn
Jun 30, 2024 2.65 Mn
API Access

Mustang Bio Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=MBIO&period=max&api_key=YOUR_API_KEY